ArticleThe American journal of tropical medicine and hygiene2011
Economic value of dengue vaccine in Thailand.
Article in The American journal of tropical medicine and hygiene, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Approaches to economic evaluations of complex interventions in thailand: a systematic review.BMC public health · 2025Pooled it
- Assessing the Economics of Dengue: Results from a Systematic Review of the Literature and Expert Survey.PharmacoEconomics · 2015Pooled it
- Economic and disease burden of dengue in Southeast Asia.PLoS neglected tropical diseases · 2013Pooled it
- Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine.The American journal of tropical medicine and hygiene · 2017Trial
- Cost-effectiveness and budget impact analyses of dengue vaccination in Indonesia.PLoS neglected tropical diseases · 2021Article
- Reducing dengue fever cases at the lowest budget: a constrained optimization approach applied to Thailand.BMC public health · 2021Article
- The Effect of E-Learning on the Attitude Toward Dengue Prevention and the Acceptance of Dengue Vaccination.Patient preference and adherence · 2021Article
- The economic impact and cost-effectiveness of combined vector-control and dengue vaccination strategies in Thailand: results from a dynamic transmission model.PLoS neglected tropical diseases · 2020Article
- Cost-Effectiveness of Dengue Vaccination in Indonesia: Considering Integrated Programs withInternational journal of environmental research and public health · 2020Article
- On the Use of Markov Models in Pharmacoeconomics: Pros and Cons and Implications for Policy Makers.Frontiers in public health · 2020Article
- Estimated economic impact of vaccinations in 73 low- and middle-income countries, 2001-2020.Bulletin of the World Health Organization · 2017Article
- An economic evaluation of vector control in the age of a dengue vaccine.PLoS neglected tropical diseases · 2017Article
- Cost-Effectiveness of Dengue Vaccination Programs in Brazil.The American journal of tropical medicine and hygiene · 2017Article
- The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling.PharmacoEconomics · 2017Article
- Operations research in global health: a scoping review with a focus on the themes of health equity and impact.Health research policy and systems · 2017Article
- A systems approach to vaccine decision making.Vaccine · 2017Article
- Cost-effectiveness of dengue vaccination in Yucatán, Mexico using a dynamic dengue transmission model.PloS one · 2017Article
- Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the Philippines.The American journal of tropical medicine and hygiene · 2016Article
- Economic Burden of Dengue Virus Infection at the Household Level Among Residents of Puerto Maldonado, Peru.The American journal of tropical medicine and hygiene · 2015Article
- Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
With several candidate dengue vaccines under development, this is an important time to help stakeholders (e.g., policy makers, scientists, clinicians, and manufacturers) better understand the potential economic value (cost-effectiveness) of a dengue vaccine, especially while vaccine characteristics and strategies might be readily altered. We developed a decision analytic Markov simulation model to evaluate the potential health and economic value of administering a dengue vaccine to an individual (≤ 1 year of age) in Thailand from the societal perspective. Sensitivity analyses evaluated the effects of ranging various vaccine (e.g., cost, efficacy, side effect), epidemiological (dengue risk), and disease (treatment-seeking behavior) characteristics. A ≥ 50% efficacious vaccine was highly cost-effective [< 1× per capita gross domestic product (GDP) ($4,289)] up to a total vaccination cost of $60 and cost-effective [< 3× per capita GDP ($12,868)] up to a total vaccination cost of $200. When the total vaccine series was $1.50, many scenarios were cost saving.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.